Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity BioSpaceThe American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk.Metabolic & GLP-1Read full story pharminent June 5, 2026 (Last updated: June 5, 2026) BioSpace The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. Metabolic & GLP-1 Read full story Post navigation Previous: Medicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior AuthorizationNext: Roche doubles down on BTK with $2.3bn Nurix deal Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026